Novo Nordisk's patent expired allowing for cheaper weight-loss drugs in India. Over 40 Indian firms are expected to launch over 50 brands within weeks, widening access in a price-sensitive market. However, concerns have been raised about misuse and confusion among prescribers as costs fall sharply. India's drug regulator did not respond to a request for comment. The country's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030, according to estimates. Indian generic drugmakers, known globally for producing low-cost medicines, are likely to price their generics at discounts of at least 50% to 60%.